Matthias Alder - 01 Jul 2023 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role: Chief Executive Officer, Director
Signature: /s/ Jason Minio, Attorney-in-Fact
Issuer symbol: GANX
Transactions as of: 01 Jul 2023
Transactions value $: $0
Form type: 4
Filing time: 05 Jul 2023, 16:18:04 UTC
Previous filing: 27 Mar 2023
Next filing: 22 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GANX	Common Stock	Options Exercise		+3,300			3,300	01 Jul 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GANX	Restricted Stock Units	Options Exercise	$0	-3,300	-25%	$0	9,900	01 Jul 2023	Common Stock	3,300		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2	The RSUs vested 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.